Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PEACE-9 - ESCALATE-RT: A Phase III Randomized Study in Patients With High-risk PSA Relapse After Local Therapy Treated With Enzalutamide Plus Androgen Deprivation Therapy and Comparing MDT ± Pelvic Radiotherapy Versus no Further Treatment

NCT07782112 is registered in ClinicalTrials.gov with Ente Ospedaliero Cantonale, Bellinzona as lead sponsor.

NCT NCT07782112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07782112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PEACE-9 - ESCALATE-RT: A Phase III Randomized Study in Patients With High-risk PSA Relapse After Local Therapy Treated With Enzalutamide Plus Androgen Deprivation Therapy and Comparing MDT ± Pelvic Radiotherapy Versus no Further Treatment
Lead sponsor
Ente Ospedaliero Cantonale, Bellinzona
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
July 31, 2030
Enrollment
140 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

biochemical recurrence, oligometastatic prostate cancer, prostatic neoplasms